六款商业AI胚胎倍性风险评估算法的头对头比较
单中心回顾性队列纳入273名患者的1000枚经PGT-A检测的囊胚,用六款匿名商业AI模型(静态或视频各三款)评分。六款算法对整倍体与非整倍体的区分度中等(AUC 0.713-0.744,95%CI重叠),评分与倍性显著相关(均P<0.001),但算法间排序一致性中等。结论认为这些工具应视为相对风险分层系统而非诊断试验。
要点
- 六款商业AI算法区分整倍体与非整倍体的AUC为0.713-0.744,95%CI重叠。
- 各算法连续评分与倍性状态显著相关(均P<0.001),高分 strata 整倍体富集。
- 算法间排序一致性中等,不同系统优先选择的胚胎常不同。
核心结论
- 六款商业AI胚胎评估算法在倍性风险分层上趋同于共同性能上限。
- 这些工具应解释为相对风险分层系统而非诊断试验。
- 算法间一致性有限,选择不同算法可影响被优先排序的胚胎。
研究设计与样本
- 单中心回顾性队列研究,纳入2022至2023年273名患者的1000枚囊胚。
- 使用六款匿名商业AI模型(静态或视频各三款)评分,以滋养层活检PGT-A确定倍性。
- 采用多变量逻辑回归和ROC曲线评估性能,并分析算法内评分分层整倍体富集及排序一致性(Kendall's τ-b)。
- 按ASEBIR形态学分级和卵母细胞年龄进行亚组分析。
主要发现
- 六款算法对整倍体与非整倍体区分度中等,AUC范围0.713-0.744,95%CI重叠。
- 所有算法连续评分与倍性状态显著相关(均P<0.001)。
- 各模型高分分层与整倍体胚胎渐进富集相关,但倍性组间评分分布大幅重叠。
- 算法间排序一致性中等,不同系统优先选择的胚胎常不同。
- 上述模式在形态学分级和母亲年龄亚组中基本一致。
关键数值与推荐
- AUC范围0.713-0.744(95%CI重叠),对应1000枚PGT-A检测囊胚。
- 连续评分与倍性关联均P<0.001。
- 排序一致性采用Kendall's τ-b评估,结果为中等。
临床怎么用
- AI评分可作为无法行PGT-A时胚胎优先排序的辅助工具。
- 不应将AI评分作为诊断性倍性检测使用。
- 选择算法时需注意不同系统优先排序的胚胎可能不同。
局限性
- 单中心回顾性设计可能限制外推性。
- 使用匿名商业模型,具体算法细节未披露。
- 原文未报告算法间一致性的具体数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Do commercial artificial intelligence (AI)-based embryo assessment algorithms differ in their ability to stratify the risk of embryo ploidy, or do they converge towards a similar level of discrimination despite being developed for different clinical objectives? DESIGN: Retrospective cohort study conducted at a single IVF centre, including 1000 blastocysts from 273 patients treated between 2022 and 2023. Embryos were scored using six anonymized commercial AI models (three each of static- or video-based). Ploidy status was determined by trophectoderm biopsy followed by preimplantation genetic testing for aneuploidy (PGT-A). Performance was evaluated using multivariable logistic regression and receiver operating characteristic curves (continuous scores). Euploidy enrichment across within-algorithm score strata and rank concordance (Kendall's τ-b) were assessed, with subgroup analyses by Asociación para el Estudio de la Biología de la Reproducción morphological grade and oocyte age. RESULTS: All six algorithms showed moderate discrimination between euploid and aneuploid embryos (area under the curve range 0.713-0.744, overlapping 95% CI), and their continuous scores were significantly associated with ploidy status (all P < 0.001). For each model, higher score strata were associated with progressive enrichment of euploid embryos, despite substantial overlap in score distributions between ploidy groups. Ranking concordance between algorithms was moderate, indicating that embryos prioritized by different systems frequently differed. These patterns were broadly consistent across morphological grades and maternal age strata. CONCLUSIONS: Across 1000 PGT-A-validated blastocysts, commercial AI embryo assessment algorithms converge towards a shared ceiling of ploidy risk stratification performance. These tools should therefore be interpreted as relative risk stratification systems rather than diagnostic tests. While AI scores may support embryo prioritization when PGT-A cannot be performed, limited concordance across algorithms indicates that the choice of algorithm can influence which embryos are prioritized.
引用
- Giménez-Rodríguez C, Caparrós López-Battú B, Bori L, et al. Head-to-head comparison of six commercial artificial intelligence algorithms for embryo ploidy risk stratification in 1000 PGT-A-tested blastocysts. Reprod Biomed Online. 2026. PMID: 42526065. doi:10.1016/j.rbmo.2026.105865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。